(LFMD) LifeMD - Overview
Stock: Telehealth, Hair, Allergy, PDF, Resume
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 100% |
| Relative Tail Risk | -16.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.16 |
| Alpha | -72.64 |
| Character TTM | |
|---|---|
| Beta | 1.538 |
| Beta Downside | 1.362 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.61% |
| CAGR/Max DD | 0.24 |
Description: LFMD LifeMD December 26, 2025
LifeMD, Inc. (NASDAQ: LFMD) is a direct-to-patient telehealth firm that links U.S. consumers with licensed clinicians through a suite of digital health brands. Its two main operating segments are Telehealth-offering services such as RexMD (men’s health), ShapiroMD (hair-loss treatments), Cleared (allergy, asthma, immunology), and the LifeMD PC primary-care platform-and WorkSimpli, a SaaS portfolio that includes PDFSimpli, ResumeBuild, SignSimpli, and LegalSimpli.
In Q2 2024 the company reported total revenue of roughly $32 million, a 19% year-over-year increase driven largely by a 27% rise in Telehealth subscription volume and a 14% lift in WorkSimpli SaaS ARR. The average revenue per user (ARPU) for its telehealth services grew to $112, reflecting higher utilization of prescription-filled orders and ancillary products such as GLP-1 weight-management kits.
Key macro drivers for LifeMD include the continued expansion of the U.S. telehealth market-projected to grow at a compound annual growth rate of about 21% through 2028-and favorable reimbursement trends as Medicare and private insurers broaden coverage for virtual visits. Additionally, the broader SaaS demand in the remote-work ecosystem supports the WorkSimpli platform’s recurring revenue visibility.
For a deeper quantitative dive, you might explore the company’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -4.60m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 11.08 > 1.0 |
| NWC/Revenue: -6.17% < 20% (prev -5.34%; Δ -0.84% < -1%) |
| CFO/TA 0.20 > 3% & CFO 13.1m > Net Income -4.60m |
| Net Debt (-17.3m) to EBITDA (10.5m): -1.64 < 3 |
| Current Ratio: 0.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.2m) vs 12m ago 9.86% < -2% |
| Gross Margin: 86.96% > 18% (prev 0.90%; Δ 8606 % > 0.5%) |
| Asset Turnover: 364.3% > 50% (prev 265.9%; Δ 98.38% > 0%) |
| Interest Coverage Ratio: -0.22 > 6 (EBITDA TTM 10.5m / Interest Expense TTM 2.17m) |
Altman Z'' -15.00
| A: -0.24 (Total Current Assets 41.1m - Total Current Liabilities 56.7m) / Total Assets 66.0m |
| B: -3.76 (Retained Earnings -247.8m / Total Assets 66.0m) |
| C: -0.01 (EBIT TTM -470.7k / Avg Total Assets 69.3m) |
| D: -3.95 (Book Value of Equity -247.3m / Total Liabilities 62.6m) |
| Altman-Z'' Score: -17.98 = D |
Beneish M -2.77
| DSRI: 1.17 (Receivables 9.24m/6.05m, Revenue 252.3m/192.9m) |
| GMI: 1.03 (GM 86.96% / 89.64%) |
| AQI: 1.24 (AQ_t 0.29 / AQ_t-1 0.24) |
| SGI: 1.31 (Revenue 252.3m / 192.9m) |
| TATA: -0.27 (NI -4.60m - CFO 13.1m) / TA 66.0m) |
| Beneish M-Score: -2.77 (Cap -4..+1) = A |
What is the price of LFMD shares?
Over the past week, the price has changed by -3.09%, over one month by -25.59%, over three months by -40.30% and over the past year by -49.68%.
Is LFMD a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LFMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.3 | 194.6% |
| Analysts Target Price | 9.3 | 194.6% |
| ValueRay Target Price | 3 | -3.5% |
LFMD Fundamental Data Overview February 03, 2026
P/S = 0.6236
P/B = 118.6737
Revenue TTM = 252.3m USD
EBIT TTM = -470.7k USD
EBITDA TTM = 10.5m USD
Long Term Debt = 9.89m USD (from longTermDebt, last fiscal year)
Short Term Debt = 673.5k USD (from shortTermDebt, last quarter)
Debt = 6.53m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -17.3m USD (from netDebt column, last quarter)
Enterprise Value = 138.7m USD (156.0m + Debt 6.53m - CCE 23.8m)
Interest Coverage Ratio = -0.22 (Ebit TTM -470.7k / Interest Expense TTM 2.17m)
EV/FCF = 8.17x (Enterprise Value 138.7m / FCF TTM 17.0m)
FCF Yield = 12.24% (FCF TTM 17.0m / Enterprise Value 138.7m)
FCF Margin = 6.73% (FCF TTM 17.0m / Revenue TTM 252.3m)
Net Margin = -1.82% (Net Income TTM -4.60m / Revenue TTM 252.3m)
Gross Margin = 86.96% ((Revenue TTM 252.3m - Cost of Revenue TTM 32.9m) / Revenue TTM)
Gross Margin QoQ = 87.69% (prev 88.06%)
Tobins Q-Ratio = 2.10 (Enterprise Value 138.7m / Total Assets 66.0m)
Interest Expense / Debt = 4.02% (Interest Expense 262.5k / Debt 6.53m)
Taxrate = 21.0% (US default 21%)
NOPAT = -371.8k (EBIT -470.7k * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.73 (Total Current Assets 41.1m / Total Current Liabilities 56.7m)
Debt / Equity = 4.96 (Debt 6.53m / totalStockholderEquity, last quarter 1.31m)
Debt / EBITDA = -1.64 (Net Debt -17.3m / EBITDA 10.5m)
Debt / FCF = -1.02 (Net Debt -17.3m / FCF TTM 17.0m)
Total Stockholder Equity = -2.07m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.64% (Net Income -4.60m / Total Assets 66.0m)
RoE = 222.3% (negative equity) (Net Income TTM -4.60m / Total Stockholder Equity -2.07m)
RoCE = -6.02% (EBIT -470.7k / Capital Employed (Equity -2.07m + L.T.Debt 9.89m))
RoIC = -3.38% (negative operating profit) (NOPAT -371.8k / Invested Capital 11.0m)
WACC = 11.24% (E(156.0m)/V(162.5m) * Re(11.58%) + D(6.53m)/V(162.5m) * Rd(4.02%) * (1-Tc(0.21)))
Discount Rate = 11.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.14%
[DCF Debug] Terminal Value 57.18% ; FCFF base≈14.4m ; Y1≈9.48m ; Y5≈4.32m
Fair Price DCF = 1.50 (EV 54.7m - Net Debt -17.3m = Equity 72.0m / Shares 48.1m; r=11.24% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 81.35 | EPS CAGR: 136.5% | SUE: 1.16 | # QB: 1
Revenue Correlation: 96.93 | Revenue CAGR: 23.32% | SUE: -0.13 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=-0.175 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.14 | Chg30d=-0.305 | Revisions Net=-1 | Growth EPS=+52.6% | Growth Revenue=-5.4%